未登录

X

Xuewu Liang

Shandong University

H指数:15

被引数:923

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-07-220

PRE

Identification and experimental validation of PYCARD as a crucial PANoptosis-related gene for immune response and inflammation in COPD

IF8.1

2024-04-234

OA

Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-03-281

PRE

Development of Potent MALT1 Inhibitors Featuring a Novel 2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one Scaffold for the Treatment of B Cell Lymphoma

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-02-130

PRE

Structure-based drug discovery of novel fused- pyrazolone carboxamide derivatives as potent and selective AXL inhibitors

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-12-014

OAAI

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology

药物开发的新方向: 通过靶向嵌合体技术降解不可降解的靶标

MEDICINAL RESEARCH REVIEWS

IF11.6

2023-11-206

PRE

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity

CHEMISTRY-A EUROPEAN JOURNAL

IF3.7

2023-09-210

OAAI

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity

CHEMISTRY-A EUROPEAN JOURNAL

IF3.7

2023-08-142

PRE

Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-09-029

PRE

Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-06-285

PREAI

MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies

MALT1作为治疗淋巴瘤和其他与MALT1异常相关的疾病的有希望的靶标

MEDICINAL RESEARCH REVIEWS

IF11.6

2021-03-2516

PRE

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-02-1548

PREAI

I2-induced cascade cyclization and dearomatization of indoles for the highly efficient synthesis of iodinated and vinylic spiroindolenines

GREEN CHEMISTRY

IF9.2

2021-01-017

PRE

Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors

FUTURE MEDICINAL CHEMISTRY

IF3.4

2019-09-139

PREAI

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2019-03-2267

PREAI

Advances on graphene-based nanomaterials for biomedical applications

石墨烯基纳米材料在生物医学中的应用研究进展

MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS

IF8.1

2018-09-01121

PREAI

Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and-2 Influenza A Neuraminidases, Including a Drug-Resistant Variant

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2018-07-0255

OAAI

Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2018-07-0112

PREAI

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2018-05-2293

PREAI

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2017-06-0130

OAAI